ChemGenex signs licensing deal with Hospira

Published: 14-Dec-2009
Regulatory

Australian biotechnology group ChemGenex Pharmaceuticals and US pharmaceutical firm Hospira have entered into an exclusive agreement to license, develop and commercialise ChemGenex\'s lead cancer candidate omacetaxine mepesuccinate in Europe, the Middle East and parts of Africa.


Australian biotechnology group ChemGenex Pharmaceuticals and US pharmaceutical firm Hospira have entered into an exclusive agreement to license, develop and commercialise ChemGenex's lead cancer candidate omacetaxine mepesuccinate in Europe, the Middle East and parts of Africa.

Applications for marketing approval of the product have been accepted for regulatory review in both the US and Europe for treatment of patients with chronic myeloid leukemia (CML) who have failed to respond to current treatment, imatinib mesylate, and who also have a particular leukaemia mutation.

Under the terms of the deal, Hospira will make an initial payment of Euro 11.1m (A$17.8m), with the potential for up to an additional €74.1m (A$119.4m) in performance milestone payments based on the successful development and commercialisation of omacetaxine. Hospira will also pay ChemGenex a royalty on product sales following commercialisation.

ChemGenex is to complete registration of omacetaxine in its initial indication with the European Medicines Agency (EMEA), while Hospira and ChemGenex will collaborate to explore future applications in a variety of haematological malignancies.

"We are very pleased to announce this important agreement, in keeping with our corporate strategy of partnering in Europe and other parts of the world, as we prepare for the launch of omacetaxine in the US, if approved," said Greg Collier, chief executive of ChemGenex.

"We look forward to working with the Hospira team to realise omacetaxine's potential in the haematology/oncology space in Europe."

  • Companies:
  • Hospira
See more

You may also like

Regulatory

FDA cautions Pfizer subsidiary in India in quality control warning letter

Read more
The letter is the result of an inspection at Hospira Healthcare India that identified GMP violations in quality control, data integrity, and microbial control

Trending Articles

  1. Accelerating and enhancing toxicology assessments Infographic guides users through ToxHQ’s speedy assessment features
  2. The right validation model: practical considerations and applications It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey
  3. Asahi Kasei Pharma grows its global portfolio with anti-CX3CR1 license The licensing deal with Chiome enhances its open innovation platform
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  5. EU GMP Annex 1: What's new for cleaning and disinfection The revised Annex 1 of the GMP guidelines is close to publication. Here, James Tucker, Ecolab Life Sciences, explores the potential impacts on cleaning and disinfection regimes within sterile manufacturing areas

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Regulatory

FDA cautions Pfizer subsidiary in India in quality control warning letter

The letter is the result of an inspection at Hospira Healthcare India that identified GMP violations in quality control, data integrity, and microbial control
Regulatory

Brussels explains why it approved Pfizer/Hospira deal

Pfizer made a commitment to remove possible product overlaps between the two companies
Regulatory

Hospira calls for biosimilars to have same name as biologicals

Different names for a biologic and the biosimilar medicine patterned on that biologic could create confusion among clinicians
Manufacturing

Hospira recalls 10 lots of Mitoxantrone

The Lake Forest, Illinois company cites sub-potency and out-of-specification impurities
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

NCEs target cancer

As the number of NCE approvals continues to rise, researchers are looking increasingly at anticancer treatments, particularly those involving new tyrosine kinase inhibitors. Dr Sarah Houlton sums up the latest arrivals on the scene
Regulatory

Biosimilars need the same names as original biologics

Proper naming of biosimilars is key for patient access and safety, say delegates at WHO INN meeting
Regulatory

Hospira's Retacrit receives Marketing Authorisation in the EU

<p>The European Commission has authorised US company Hospira, a world leader in generic injectable pharmaceuticals, to market Retacrit (epoetin zeta), a biosimilar erythropoietin, for the treatment of anemia associated with chronic renal failure (administered intravenously) and chemotherapy. </p>
Subscribe now